Drugs /

day101

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available inhibitor of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor TAK-580 inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.

Clinical Trials

View Clinical Trials for day101

Day101 has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating day101, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

ARAF Mutation, BRAF Fusion, and BRAF K601E are the most frequent biomarker inclusion criteria for day101 clinical trials.

Low grade glioma and malignant solid tumor are the most common diseases being investigated in day101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Day101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating day101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mln-2480, tak580, pan-raf kinase inhibitor tak-580, biib-024, (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide, mln2480, day 101, day-101, pan-raf kinase inhibitor day101, tak-580
Drug Categories [2]:
BRAF inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
ARAF, BRAF, RAF1
NCIT ID [1]:
C106254

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.